Patent intelligence · Companies
Company patent strength
Non-educational filers ranked by their patent portfolio. Grant rate and lapsed share expose where high filing volume is not matched by granted patents. Domestic filers lead — toggle to foreign applicants to see who is entering the Indian market.
Free to browse the ranking. Sign into open a filer's full profile — inventors, filing trend and quality index. See how we rank.
Why this page exists — and how to read it
Filing volume and IP quality are different things. This leaderboard ranks non-educational filers by portfolio, but the grant-rate and lapsed sorts are where the judgement lives: they separate companies whose filings survive examination from those accumulating paper.
- Investors
- High grant rate on steady filing usually means a real R&D engine; big volume with a high lapsed share is a red flag worth asking about.
- Founders & operators
- These are the incumbents and potential acquirers in your space — open a filer to see the walls you'd build against.
- Corporate & R&D
- Benchmark competitors' portfolios and grant rates; toggle to foreign to watch who is entering the Indian market.
💬 The grant-rate sort applies a 20-filing floor so tiny portfolios can't top the list.
3,207 foreign filers with 5+ patents · page 20
| # | Filer | Patents↓ | Granted↓ | Lapsed↓ | Pending↓ | Active |
|---|---|---|---|---|---|---|
| 951 | KOHLER MIRA | 16 | 425% | 0 | 12 | 2021–2025 |
| 952 | MANITOU ITALIA S R L | 16 | 16.3% | 0 | 15 | 2020–2025 |
| 953 | MIRUS | 16 | 00% | 0 | 16 | 2024–2026 |
| 954 | NIDEC MOBILITY | 16 | 00% | 1 | 15 | 2022–2025 |
| 955 | NOVAMONT | 16 | 16.3% | 0 | 15 | 2022–2026 |
| 956 | OETIKER NY | 16 | 531.3% | 1 | 10 | 2022–2026 |
| 957 | ONO PHARMACEUTICAL | 16 | 16.3% | 1 | 14 | 2022–2026 |
| 958 | PILOT ALSO TRADING AS PILOT | 16 | 16.3% | 1 | 14 | 2022–2026 |
| 959 | RADIOMETER MEDICAL APS | 16 | 16.3% | 0 | 15 | 2022–2026 |
| 960 | REC SOLAR | 16 | 00% | 0 | 16 | 2023–2024 |
| 961 | RECKITT COLMAN OVERSEAS HYGIENE HOME | 16 | 00% | 0 | 16 | 2022–2025 |
| 962 | REPLIGEN | 16 | 531.3% | 2 | 9 | 2022–2026 |
| 963 | RITE HITE HOLDING | 16 | 212.5% | 0 | 14 | 2020–2026 |
| 964 | RITTAL KG | 16 | 318.8% | 1 | 12 | 2022–2026 |
| 965 | SAVIO MACCHINE TESSILI | 16 | 212.5% | 0 | 14 | 2020–2024 |
| 966 | SCH CO INTERNATIONAL KG | 16 | 00% | 0 | 16 | 2024–2025 |
| 967 | SENSILE MEDICAL | 16 | 16.3% | 1 | 14 | 2022–2025 |
| 968 | SIDEL PARTICIPATIONS | 16 | 00% | 0 | 16 | 2022–2025 |
| 969 | SOLTEC INNOVATIONS S L | 16 | 00% | 8 | 8 | 2022–2023 |
| 970 | SPRINGWORKS THERAPEUTICS | 16 | 00% | 0 | 16 | 2022–2025 |
| 971 | SYSTIMMUNE | 16 | 16.3% | 0 | 15 | 2020–2026 |
| 972 | TRELLEBORG SEALING SOLUTIONS GERMANY | 16 | 16.3% | 1 | 14 | 2022–2025 |
| 973 | UBE | 16 | 00% | 0 | 16 | 2022–2026 |
| 974 | UNITED THERAPEUTICS | 16 | 212.5% | 1 | 13 | 2022–2026 |
| 975 | VARONIS SYSTEMS | 16 | 00% | 0 | 16 | 2023–2026 |
| 976 | VIAVI SOLUTIONS | 16 | 425% | 1 | 11 | 2022–2025 |
| 977 | VIRSEC SYSTEMS | 16 | 00% | 0 | 16 | 2023–2024 |
| 978 | WAVE LIFE SCIENCES | 16 | 00% | 1 | 15 | 2022–2026 |
| 979 | XIAMEN AMPACK TECHNOLOGY | 16 | 00% | 0 | 16 | 2023–2026 |
| 980 | AC IMMUNE | 15 | 00% | 1 | 14 | 2022–2025 |
| 981 | ALIBABA CHINA | 15 | 00% | 0 | 15 | 2024–2026 |
| 982 | ARRIS ENTERPRISES | 15 | 00% | 6 | 9 | 2022–2024 |
| 983 | BICYCLETX | 15 | 16.7% | 4 | 10 | 2019–2025 |
| 984 | BR CKNER MASCHINENBAU | 15 | 213.3% | 0 | 13 | 2022–2025 |
| 985 | CELLFORCE GROUP | 15 | 00% | 0 | 15 | 2024–2026 |
| 986 | CUREXO | 15 | 213.3% | 0 | 13 | 2022–2026 |
| 987 | CYTOKINETICS | 15 | 16.7% | 3 | 11 | 2022–2025 |
| 988 | DEEPSIGHT TECHNOLOGY | 15 | 00% | 0 | 15 | 2022–2026 |
| 989 | EQUASHIELD MEDICAL | 15 | 16.7% | 0 | 14 | 2022–2026 |
| 990 | FETTE COMPACTING | 15 | 213.3% | 0 | 13 | 2021–2026 |
| 991 | GE VERNOVA INFRASTRUCTURE TECHNOLOGY | 15 | 00% | 0 | 15 | 2025–2026 |
| 992 | GEA PROCESS ENGINEERING A S | 15 | 213.3% | 0 | 13 | 2023–2026 |
| 993 | GENERAL MILLS | 15 | 00% | 0 | 15 | 2022–2025 |
| 994 | GIESECKE DEVRIENT ADVANCE52 | 15 | 00% | 0 | 15 | 2024–2026 |
| 995 | GOGORO | 15 | 320% | 1 | 11 | 2021–2024 |
| 996 | H B FULLER | 15 | 320% | 0 | 12 | 2021–2026 |
| 997 | HANGZHOU BRONCUS MEDICAL | 15 | 320% | 2 | 10 | 2021–2023 |
| 998 | HANWHA VISION | 15 | 960% | 0 | 6 | 2022–2026 |
| 999 | HYTEM | 15 | 213.3% | 0 | 13 | 2022–2024 |
| 1000 | INTERCONTINENTAL GREAT BRANDS | 15 | 213.3% | 0 | 13 | 2022–2026 |
Educational institutes are excluded — see the institute leaderboard. Attribution is by patent assignee record; a jointly-owned patent is credited to each co-owner, so a co-filed patent counts for every company on it. "Lapsed" = abandoned, withdrawn, deemed-withdrawn or refused; "Pending" = awaiting examination or in prosecution. Want to filter by technology or value category? Browse the filer explorer →
Rankings use patent-registry status (grant rate, examination, claim depth) as a quality proxy — directional, not advice; see methodology. Read the ranking methodology →